论文部分内容阅读
目的探讨促肝细胞生长素治疗结核药物性肝损害的疗效及临床分析。方法 2011年8月至2012年8月期间,我院诊治的66例结核药物性肝损害患者,随机将其分为对照组(常规保肝治疗)和观察组(静脉滴注促肝细胞生长素),每组各33例,治疗4周,对两组治疗前后肝功能,以及肝功恢复比率,进行观察和比较。结果与对照组相比,观察组丙氨酸氨基转移酶(ALT)和总胆红素(TBIL)水平明显降低,肝功恢复正常比率明显升高,P<0.05,差异有统计学意义。结论促肝细胞生长素治疗结核药物性肝损害疗效显著,明显改善患者的预后质量,值得临床推广。
Objective To investigate the curative effect and clinical analysis of hepatocyte growth-promoting hormone in treatment of drug-induced liver damage in tuberculosis. Methods From August 2011 to August 2012, 66 patients with drug-induced liver damage were randomly divided into control group (conventional hepatoprotective therapy) and observation group (intravenous injection of hepatocyte growth-promoting hormone ), 33 cases in each group for 4 weeks. The liver function and the recovery rate of liver function before and after treatment were observed and compared. Results Compared with the control group, the levels of ALT and TBIL in the observation group were significantly decreased, and the normal rate of liver function recovery was significantly increased (P <0.05). The difference was statistically significant. Conclusions Prompt therapeutic effect of hepatocyte growth-regulating drug on tuberculosis drug-induced liver injury can obviously improve the quality of prognosis of patients, which is worthy of clinical promotion.